ASHG:Nabsys 以 EGM 连接细胞遗传学与基因组学,绘制血液癌症图谱
ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers
Nabsys 在 ASHG 2026 年会上分享电子基因组图谱(EGM)在血液恶性肿瘤中的初步数据,并预览面向该应用的分析软件。公司称 EGM 运行于 OhmX 平台,可提供结构变异与拷贝数变异的高分辨率全基因组视图,定位为现有工具的补充而非替代。Navigator 云平台含 SV-Discover 和 SV-Verify,分别用于全基因组结构变异分析与验证其他技术标记的变异。
Blood cancers are often driven by large-scale genomic rearrangements, including translocations, deletions, duplications, and other structural and copy number changes, that no single assay captures well. In practice, characterizing a hematologic malignancy can mean piecing together results from karyotyping, fluorescence in situ hybridization (FISH), chromosomal microarray, and sequencing, each with its own resolution limits and blind spots.
Nabsys is positioning its Electronic Genome Mapping (EGM) technology as one way to close some of those gaps. At the American Society of Human Genetics (ASHG) 2026 Annual Meeting, held October 20–24 in Montréal, the Providence, RI-based company shared preliminary data on EGM in hematologic malignancies and previewed analysis software built for that application.
Bridging two disciplines
In a Nabsys-sponsored CoLab session on October 22, Alka Chaubey, PhD, FACMG, the company’s chief medical and genomics officer, presented “Electronic Genome Mapping in Hematologic Malignancies: Bridging Cytogenetics and Molecular Genomics” on behalf of Brynn Levy, MSc(Med), PhD, FACMG, of Columbia University. The talk covered early findings on how well EGM detects structural and copy number variants, including how its results compared with established cytogenetic methods.
The work builds on OhmX Platform installations at Columbia University Medical Center, awarded through the RAMP UP Program from Hitachi High-Tech America and Nabsys. Running on OhmX, EGM is designed to give a high-resolution, genome-wide view of structural and copy number variation. Nabsys frames the technology as a complement to existing tools rather than a replacement.
“Researchers need a more complete view of the complex genomic changes in hematologic cancers,” said Barrett Bready, MD, Nabsys’s founder and CEO. “These preliminary findings highlight EGM’s potential to complement established methods.”
Software shaped by users
Alongside the data, Nabsys demonstrated Nabsys Navigator
, its cloud-based platform for EGM analysis and visualization. Navigator includes two pipelines: SV-Discover
, for genome-wide structural variant analysis, and SV-Verify
, for confirming structural variants flagged by other technologies. Booth visitors could also preview the company’s forthcoming hematologic malignancy analysis software, the same tool used to analyze samples in Chaubey’s presentation, and weigh in on its development. Bready said the company is “pairing that work with software development shaped directly by the researchers who will use it.” The OhmX Platform is for research use only and is not intended for diagnostic procedures.
The post ASHG: Nabsys Links Cytogenetics and Genomics to Map Hematologic Cancers appeared first on GEN - Genetic Engineering and Biotechnology News.
来源:GEN 新闻 · genengnews.com